Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer

Fig. 2

Survival analysis and ColXα1 expression by IHC in current study (top). The DFS and OS were significantly different between high ColXα1 (103 patients) and low ColXα1 (61 patients) ER+/HER+ tumors. Survival analysis in the TCGA ER+/HER2+ tumor dataset (bottom).. Patients stratified into higher (49 patients) and lower (55 patients) than the median of COL10A1 mRNA expression showed significantly different DFS and OS

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us